E

When IO, targeted therapy and oncogene worlds collide

Oncogenes and tumour suppressors can have surprising effects on targeted therapies and immunotherapies

November 20, 2020
E

Notes from a small island

new approaches to applying translational research to the clinic in oncology R&D

November 3, 2020
E

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020
E

ESMO20 Preview 1 – Key progress in biomarker development

A look at progress and new developments in cancer biomarker developments

September 9, 2020
E

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020
E

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020
E

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020
E

Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020
E

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020
E

Alternative cell therapy approaches to tackling cancer

How can we go about improving cell therapy approaches?

March 26, 2020
E

A core strategy or trick play in cancer research?

Manipulating immune cells in order to harness great antitumour responses to immunotherapy

March 5, 2020
E

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020
E

Under the Radar

An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy

February 28, 2020
E

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020
E

Whipping up a frenzy in CAR-T cell future developments

In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours

February 13, 2020
E

Can we target p53 therapeutically?

What's new about p53 mutants and MDM2 inhibitors?

February 7, 2019
E

Book Review – L’Immunothérapie des cancers

Should you read a book on the History of Cancer Immunotherapy? Here's our review...

February 5, 2019
E

New developments in cytokines as immune modulators

New insights emerging from research on cytokines as an effective way to induce anti tumour immunity

January 31, 2019
E

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018
E

When oncogenic and immunogenic worlds collide…

Five key recent papers that are well worth looking at and what the science teaches us about next directions

July 25, 2018
E

Under the hood – a look at important new cancer research

Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...

June 25, 2018
E

Key trends in oncology R&D for 2018 – Part 1

New series on Key Trends in Oncology for 2018

January 4, 2018
E

Some simply stunning cancer research for Journal Club

Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.

November 3, 2017
E

August 2017 BSB Journal Club on Breast Cancer

After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...

August 22, 2017
E

The Science of PD1 PDL1 Cancer Immunotherapy

The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.

November 26, 2014
E

July Journal Club

July Journal Club explores some intriguing new data around a cancer immunotherapy theme

July 7, 2017
E

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017
E
Ira Mellman Dan Chen Authors of Cancer Immunity Cycle

Understanding the Cancer-Immune Set Point

A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.

February 22, 2017
E

Journal Club – February 2017

A look at what we can learn from some recently published new papers in the oncology space.

February 9, 2017
E

August Journal Club – Cancer Immunotherapy

Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion

August 25, 2016